Jump to content
Sermorelin Chemical

A schematic readout of the sermorelin literature — the GHRH(1-29) secretagogue panel laid out like a control board, with each pituitary-axis finding wired to its source and the comparisons with ipamorelin and CJC-1295 traced as adjacent circuits.

MODULE 08 / ABOUT

About Sermorelin Chemical.

A bench log that reads the GHRH(1-29) research record straight — no clinic, no counter, no prescription.

Read the researchContact

What this site is

Sermorelin Chemical is a bench log for one molecule — an assay notebook that records what the peer-reviewed sermorelin (GHRH(1-29)) literature actually measured, each entry traced to the study behind it. It is a publication, not a supplier: nothing here is synthesized, stocked, priced, or shipped, and no clinic, prescriber, or dosing service is attached to it. The writing summarizes published science and stops where the data stop; it does not diagnose, treat, or advise.

The site is built like a control board on purpose: each finding is pressed into its own module and wired back to its study, so the structure of the evidence is visible at a glance. Where the data is strong — the pediatric height-velocity result [1], the GH/IGF-1 reversal in older men [2], the pharmacokinetic characterization [3] — we say so plainly. Where it stops, we leave the gap lit rather than fill it in.

What the name means

The word "chemical" in this site's name is editorial framing — it signals a sober, analytical reading of sermorelin as a research compound, identified by its sequence, molecular weight, and CAS number rather than by any brand. It is not a claim that this site supplies a chemical, fills a prescription, or operates a pharmacy. The compound described here is research-grade GHRH(1-29) supplied for laboratory study; the regulatory and access questions belong to the published record and to qualified professionals, not to this editorial project.

How we handle the evidence

Three editorial commitments shape every page. First, every quantitative claim carries a citation to a specific study, with PMID or DOI in the references register. Second, we keep the well-established findings separate from the marketed-but-unproven ones — sermorelin's anti-aging and body-composition marketing outpaces the rigorous long-term evidence, and an Annals of Internal Medicine editorial called secretagogue use for aging "not yet ready for prime time" [5]. Third, we state the regulatory history accurately: sermorelin was FDA-approved for pediatric GH deficiency and withdrawn from the US market in 2008 for commercial reasons, not safety or efficacy, and is now prepared by compounding pharmacies. We describe research findings; we do not recommend doses for humans.